Managing patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Many men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia can be managed safely and effectively by primary care providers. After a basic evaluation to exclude other diseases that may cause lower urinary tract symptoms, quantifying the degree of symptoms and bother, and perhaps making an assessment of prostate size, the primary care provider can determine which men require immediate evaluation by a urologist and which men may choose among various treatment options, including watchful waiting and various single agent or combination medication strategies. Recent information about risk factors for disease progression has also helped to inform patient decisions on which treatment option is best for the individual patient. The purpose of this review is to provide primary care providers with an approach to the management of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
McNaughton-Collins
Mary
M
General Medicine Division, Massachusetts General Hospital, Boston, Mass 02114, USA.
Barry
Michael J
MJ
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D018450:Disease Progression; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D008297:Male; D010347:Patient Care Planning; D010808:Physical Examination; D017410:Practice Guidelines as Topic; D017430:Prostate-Specific Antigen / Q000032:analysis; D011470:Prostatic Hyperplasia / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011471:Prostatic Neoplasms / Q000150:complications / Q000175:diagnosis; D012307:Risk Factors; D014463:Ultrasonography; D016482:Urinalysis; D014555:Urination Disorders / Q000209:etiology*; D014563:Urodynamics
D000317:Adrenergic alpha-Antagonists; D004791:Enzyme Inhibitors; D017430:Prostate-Specific Antigen